CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
Authors:
- Paul LinPLPaul Lin
- Sunil AcharyaSASunil Acharya
- Francia Reyes-SilvaFRFrancia Reyes-Silva
- Rafet BasarRBRafet Basar
- Nadima UpretyNUNadima Uprety
- Luz Yurany Moreno RuedaLRLuz Yurany Moreno Rueda
- Pei LinPLPei Lin
- April L. GilbertAGApril L. Gilbert
- Pinaki P. BanerjeePBPinaki P. Banerjee
- Dexing FangDFDexing Fang
- Chenyu ZhangCZChenyu Zhang
- Ana Karen Nunez CortesACAna Karen Nunez Cortes
Open Access
- 27 October 2025
- journal article
- immunology
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (2) , 234-249
Abstract
CD70 is highly expressed in many cancers, including multiple myeloma. We show in two cohorts of patients with multiple myeloma that CD70 is elevated in several high-risk disease categories and correlates with poor survival. These findings were validated using single-cell RNA sequencing, flow cytometry, and IHC. Moreover, we demonstrate the feasibility of targeting CD70 in myeloma using NK cells engineered with a chimeric antigen receptor (CAR) incorporating the CD70 cognate receptor CD27 and IL-15 (CAR27/IL-15). CAR27/IL-15 NK cells exerted potent in vitro and in vivo cytotoxicity against CD70+ multiple myeloma cells, comparable with CAR27/IL-15 T cells, and remained effective in BCMA knockout models. Collectively, these results establish CD70 as a promising therapeutic target for high-risk multiple myeloma, particularly for patients who relapse after BCMA-directed therapy, providing preclinical support for the ongoing phase I/II clinical trial of CD70-targeting CAR NK cells (NCT05092451). Significance: We demonstrate that CD70 expression is elevated in patients with high-risk multiple myeloma and in patients with t(4;14) translocation. CD70-targeting CAR NK cells exhibit potent cytotoxicity against CD70+ multiple myeloma cells and significantly improve survival in xenograft mouse models of multiple myeloma, even in the absence of BCMA expression. See related commentary by Benson Jr and Caligiuri, p. 166Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01 CA280827)
- National Cancer Institute (5 P01CA148600-03)
- National Cancer Institute (P30 CA16672)
- Leukemia and Lymphoma Society (SCOR-12206-17)
- National Cancer Institute (R01 CA211044)
- University of Texas MD Anderson Cancer Center
- Conquer Cancer Foundation
- Multiple Myeloma Research Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Paula and Rodger Riney Foundation
This publication has 41 references indexed in Scilit:
- Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targetsCell Reports Medicine, 2025
- Single cell clonotypic and transcriptional evolution of multiple myeloma precursor diseaseCancer Cell, 2023
- CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistanceCancer Cell, 2023
- NK cell therapy in relapsed refractory multiple myelomaClinical Immunology, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2019
- Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in MyelomaLeukemia Research, 2018
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia, 2017
- Massively parallel digital transcriptional profiling of single cellsNature Communications, 2017